466 related articles for article (PubMed ID: 17283264)
1. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
2. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
Shepherd J
Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
[TBL] [Abstract][Full Text] [Related]
5. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
6. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
9. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
Rothenbacher D; Koenig W; Brenner H
Arch Intern Med; 2006 Dec 11-25; 166(22):2455-60. PubMed ID: 17159010
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study.
Cushman M; Arnold AM; Psaty BM; Manolio TA; Kuller LH; Burke GL; Polak JF; Tracy RP
Circulation; 2005 Jul; 112(1):25-31. PubMed ID: 15983251
[TBL] [Abstract][Full Text] [Related]
15. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
16. Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study.
Straczek C; Ducimetiere P; Barberger-Gateau P; Helmer C; Ritchie K; Jouven X; Carcaillon L; Amouyel P; Tzourio C; Empana JP
J Am Geriatr Soc; 2010 Jan; 58(1):129-35. PubMed ID: 20002508
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.
Rutter MK; Meigs JB; Sullivan LM; D'Agostino RB; Wilson PW
Circulation; 2004 Jul; 110(4):380-5. PubMed ID: 15262834
[TBL] [Abstract][Full Text] [Related]
18. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study.
van der Meer IM; de Maat MP; Kiliaan AJ; van der Kuip DA; Hofman A; Witteman JC
Arch Intern Med; 2003 Jun; 163(11):1323-8. PubMed ID: 12796068
[TBL] [Abstract][Full Text] [Related]
19. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
Mora S; Rifai N; Buring JE; Ridker PM
Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.
Margolis KL; Manson JE; Greenland P; Rodabough RJ; Bray PF; Safford M; Grimm RH; Howard BV; Assaf AR; Prentice R;
Arch Intern Med; 2005 Mar; 165(5):500-8. PubMed ID: 15767524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
